pubmed.ncbi.nlm.nih.gov

N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo - PubMed

️Sat Jan 01 2000

N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo

U Andersson et al. Biochem Pharmacol. 2000.

Abstract

N-Butyldeoxynojirimycin (NB-DNJ) inhibits the ceramide glucosyltransferase which catalyses the first step in glycosphingolipid (GSL) biosynthesis. It has the potential to be used for the treatment of the GSL lysosomal storage diseases and is currently in clinical trials for the treatment of type 1 Gaucher's disease. However, NB-DNJ is also a potent inhibitor of other enzymes, including alpha-glucosidase I and II, which could potentially cause side effects in patients receiving life-long therapy. Wetherefore evaluated a potentially more selective GSL biosynthesis inhibitor, N-butyldeoxygalactonojirimycin (NB-DGJ), in vitro and in vivo. The distribution and degree of GSL depletion in the liver of mice treated with NB-DGJ or NB-DNJ were equivalent. Mice treated with NB-DGJ had normal body weights and lymphoid organ sizes, whereas NB-DNJ-treated mice showed weight loss and partial lymphoid organ shrinkage. NB-DNJ inhibited glycogen catabolism in the liver, whereas NB-DGJ did not. NB-DNJ was also a potent inhibitor of sucrase and maltase in vitro but not of lactase, while NB-DGJ inhibited lactase but not sucrase or maltase. NB-DGJ is therefore more selective than NB-DNJ, and deserves to be evaluated for human therapy.

PubMed Disclaimer

Cited by

Evaluation of N-nonyl-deoxygalactonojirimycin as a pharmacological chaperone for human GM1 gangliosidosis leads to identification of a feline model suitable for testing enzyme enhancement therapy.
Rigat BA, Tropak MB, Buttner J, Crushell E, Benedict D, Callahan JW, Martin DR, Mahuran DJ. Rigat BA, et al. Mol Genet Metab. 2012 Sep;107(1-2):203-12. doi: 10.1016/j.ymgme.2012.06.007. Epub 2012 Jun 19. Mol Genet Metab. 2012. PMID: 22784478 Free PMC article.
Small-molecule therapeutics for the treatment of glycolipid lysosomal storage disorders.
Butters TD, Mellor HR, Narita K, Dwek RA, Platt FM. Butters TD, et al. Philos Trans R Soc Lond B Biol Sci. 2003 May 29;358(1433):927-45. doi: 10.1098/rstb.2003.1278. Philos Trans R Soc Lond B Biol Sci. 2003. PMID: 12803927 Free PMC article. Review.
1,6-epi-Cyclophellitol Cyclosulfamidate Is a Bona Fide Lysosomal α-Glucosidase Stabilizer for the Treatment of Pompe Disease.
Kok K, Kuo CL, Katzy RE, Lelieveld LT, Wu L, Roig-Zamboni V, van der Marel GA, Codée JDC, Sulzenbacher G, Davies GJ, Overkleeft HS, Aerts JMFG, Artola M. Kok K, et al. J Am Chem Soc. 2022 Aug 17;144(32):14819-14827. doi: 10.1021/jacs.2c05666. Epub 2022 Aug 2. J Am Chem Soc. 2022. PMID: 35917590 Free PMC article.
Understanding and modifying Fabry disease: Rationale and design of a pivotal Phase 3 study and results from a patient-reported outcome validation study.
Wanner C, Kimonis V, Politei J, Warnock DG, Üçeyler N, Frey A, Cornelisse P, Hughes D. Wanner C, et al. Mol Genet Metab Rep. 2022 Mar 26;31:100862. doi: 10.1016/j.ymgmr.2022.100862. eCollection 2022 Jun. Mol Genet Metab Rep. 2022. PMID: 35782623 Free PMC article.
Substrate reduction therapy of glycosphingolipid storage disorders.
Aerts JM, Hollak CE, Boot RG, Groener JE, Maas M. Aerts JM, et al. J Inherit Metab Dis. 2006 Apr-Jun;29(2-3):449-56. doi: 10.1007/s10545-006-0272-5. J Inherit Metab Dis. 2006. PMID: 16763917

N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo - PubMed